How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia.

Abstract excerpt

ABSTRACT: Mutations in MYD88 (95%-97%) and CXCR4 (30%-40%) are common in Waldenström macroglobulinemia (WM). TP53 is altered in 20% to 30% of patients with WM, particularly those previously treated. Mutated MYD88 activates hematopoietic cell kinase that drives Bruton tyrosine kinase (BTK) prosurvival signaling. Both nonsense and frameshift CXCR4 mutations occur in WM. Nonsense variants show greater resistance to...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Agammaglobulinaemia Tyrosine Kinase
• Share to Myeloid Differentiation Factor 88